Citadel Advisors LLC Acquires Shares of 12,267 Burning Rock Biotech Limited (NASDAQ:BNR)

Citadel Advisors LLC acquired a new stake in Burning Rock Biotech Limited (NASDAQ:BNR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,267 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.12% of Burning Rock Biotech at the end of the most recent quarter.

Separately, Crcm LP purchased a new stake in shares of Burning Rock Biotech in the 4th quarter valued at approximately $2,200,000. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

Burning Rock Biotech Trading Up 7.3%

Shares of NASDAQ:BNR opened at $3.24 on Wednesday. Burning Rock Biotech Limited has a 52 week low of $2.18 and a 52 week high of $7.90. The company’s 50 day moving average is $2.97 and its two-hundred day moving average is $5.12. The company has a market cap of $34.87 million, a PE ratio of -1.08 and a beta of 0.74.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings data on Friday, June 6th. The company reported ($0.17) EPS for the quarter. Burning Rock Biotech had a negative net margin of 83.50% and a negative return on equity of 60.68%. The firm had revenue of $18.34 million during the quarter.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.